M-A: Among patients with kidney failure treated with dialysis, mineralocorticoid receptor antagonists reduce cardiovascular and all-cause mortality without increasing the risk of hyperkalemia.
15 Jun, 2021 | 08:53h | UTCEfficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
Patients with kidney failure have a high risk of cardiovascular diseases. This meta-analysis suggests that mineralocorticoid receptor antagonists might improve clinical outcomes of patients with kidney failure without a major increase in hyperkalemia risk https://t.co/o3aO3KK2S6 pic.twitter.com/5xuCgs6FbQ
— CJASN (@CJASN) June 14, 2021